New β-Lactamase Inhibitors in the Clinic

Infectious Disease Clinics of North America

Volumn 30, Issue 2, 2016, Pages 441-464

  Papp Wallace, Krisztina M ^a,b   Bonomo, Robert A ^a,b  

^a LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Boronic acids; Carbapenems; Diazabicyclooctanones; Inhibitor; Metallo beta lactamases; Monobactams; Sulfones; Lactamases

Indexed keywords

3' THIOBENZOYL CEPHALOSPORIN; 3,4 DIHYDRO 2H BENZO[E][1,2] OXABORININE 8 CARBOXYLIC ACID; AA 101; ALPHA AMINOBORONIC ACID; AVIBACTAM; AVIBACTAM PLUS CEFTAZIDIME; BAL 30072; BAL 30376; BENZO(B)THIOPHENE 2 BORONIC ACID; BETA LACTAMASE INHIBITOR; BORONIC ACID DERIVATIVE; CEFTOLOZANE PLUS TAZOBACTAM; CEPHALOSPORIN DERIVATIVE; DIAZABICYCLOOCTANONE DERIVATIVE; FPI 1465; FSI 1686; ME 1071; MG 96077; MK 8712; RELEBACTAM; RG 6080; S 02030; SIDEROPHORE; SYN 2190; UNCLASSIFIED DRUG; WCK 4234; WCK 5153; WO 2013/030735; ANTIINFECTIVE AGENT; AZABICYCLO DERIVATIVE; SULFONE;

AMINO ACID SUBSTITUTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; DRUG PENETRATION; DRUG STRUCTURE; DRUG TRANSPORT; ESCHERICHIA COLI; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; REVIEW; SURVIVAL RATE; DRUG EFFECTS; ENZYMOLOGY; GRAM NEGATIVE BACTERIUM; GRAM-NEGATIVE BACTERIAL INFECTIONS; MICROBIOLOGY; PATHOGENICITY;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAM RESISTANCE; BETA-LACTAMASE INHIBITORS; BORONIC ACIDS; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; SULFONES;

EID: 84991290250     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2016.02.007     Document Type: Review

References (81)

1. 1 Drawz, S.M., Papp-Wallace, K.M., Bonomo, R.A., New β-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother 58 (2014), 1835–1846.
2. 2 Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Twenty-fifth Informational supplement M100-S25. Wayne (PA): CLSI; 2015.
3. 3 Drawz, S.M., Bonomo, R.A., Three decades of β-lactamase inhibitors. Clin Microbiol Rev 23 (2010), 160–201.
4. 4 Papp-Wallace, K.M., Bethel, C.R., Distler, A.M., et al. Inhibitor resistance in the KPC-2 β-lactamase, a preeminent property of this class A β-lactamase. Antimicrob Agents Chemother 54 (2010), 890–897.
5. 5 Takeda, S., Ishii, Y., Hatano, K., et al. Stability of FR264205 against AmpC β-lactamase of Pseudomonas aeruginosa. Int J Antimicrob Agents 30 (2007), 443–445.
6. 6 Zhanel, G.G., Chung, P., Adam, H., et al. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs 74 (2014), 31–51.
7. 7 Cabot, G., Bruchmann, S., Mulet, X., et al. Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. Antimicrob Agents Chemother 58 (2014), 3091–3099.
8. 8 Berrazeg, M., Jeannot, K., Ntsogo Enguéné, V.Y., et al. Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins. Antimicrob Agents Chemother 59:10 (2015), 6248–6255.
9. 9 Aktas, Z., Kayacan, C., Oncul, O., In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents 39 (2012), 86–89.
10. 10 Livermore, D.M., Mushtaq, S., Warner, M., et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 55 (2011), 390–394.
11. 11 Mushtaq, S., Warner, M., Livermore, D.M., In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters. J Antimicrob Chemother 65 (2010), 2376–2381.
12. 12 Mushtaq, S., Warner, M., Williams, G., et al. Activity of chequerboard combinations of ceftaroline and NXL104 versus β-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 65 (2010), 1428–1432.
13. 13 Pagès, J.M., Peslier, S., Keating, T.A., et al. Role of the Outer Membrane and Porins in Susceptibility of β-Lactamase-Producing Enterobacteriaceae to Ceftazidime-Avibactam. Antimicrob Agents Chemother 60:3 (2015), 1349–1359.
14. 14 Ehmann, D.E., Jahic, H., Ross, P.L., et al. Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc Natl Acad Sci U S A 109 (2012), 11663–11668.
15. 15 Ehmann, D.E., Jahic, H., Ross, P.L., et al. Kinetics of avibactam inhibition against class A, C, and D β-lactamases. J Biol Chem 288 (2013), 27960–27971.
16. 16 Xu, H., Hazra, S., Blanchard, J.S., NXL104 irreversibly inhibits the β-lactamase from Mycobacterium tuberculosis. Biochemistry 51 (2012), 4551–4557.
17. 17 Lahiri, S.D., Mangani, S., Jahic, H., et al. Molecular basis of selective inhibition and slow reversibility of avibactam against class D carbapenemases: a structure-guided study of OXA-24 and OXA-48. ACS Chem Biol 10 (2015), 591–600.
18. 18 Lahiri, S.D., Mangani, S., Durand-Reville, T., et al. Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC β-lactamases. Antimicrob Agents Chemother 57 (2013), 2496–2505.
19. 19 King, D.T., King, A.M., Lal, S.M., et al. Molecular mechanism of avibactam-mediated β-lactamase inhibition. ACS Infect Dis 1 (2015), 175–184.
20. 20 Krishnan, N.P., Nguyen, N.Q., Papp-Wallace, K.M., et al. Inhibition of Klebsiella β-Lactamases (SHV-1 and KPC-2) by Avibactam: A Structural Study. PLoS One, 10(9), 2015, e0136813.
21. 21 Livermore, D.M., Mushtaq, S., Barker, K., et al. Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104). J Antimicrob Chemother 67 (2012), 1354–1358.
22. 22 Lahiri, S.D., Walkup, G.K., Whiteaker, J.D., et al. Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC. J Antimicrob Chemother 70 (2015), 1650–1658.
23. 23 Winkler, M.L., Papp-Wallace, K.M., Hujer, A.M., et al. Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 59 (2015), 1020–1029.
24. 24 Alm, R.A., Johnstone, M.R., Lahiri, S.D., Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3. J Antimicrob Chemother 70 (2015), 1420–1428.
25. 25 Papp-Wallace, K.M., Winkler, M.L., Taracila, M.A., et al. Variants of the KPC-2 β-lactamase which are resistant to inhibition by avibactam. Antimicrob Agents Chemother 59:7 (2015), 3710–3717.
26. 26 Winkler, M.L., Papp-Wallace, K.M., Bonomo, R.A., Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop. J Antimicrob Chemother 70:8 (2015), 2279–2286.
27. 27 Winkler, M.L., Papp-Wallace, K.M., Taracila, M.A., et al. Avibactam and inhibitor resistant SHV β-lactamases. Antimicrob Agents Chemother 59:7 (2015), 3700–3709.
28. 28 Livermore, D.M., Warner, M., Jamrozy, D., et al. In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase. Antimicrob Agents Chemother 59:9 (2015), 5324–5330.
29. 29 Humphries, R.M., Yang, S., Hemarajata, P., et al. First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate. Antimicrob Agents Chemother 59:10 (2015), 6605–6607.
30. 30 Hirsch, E.B., Ledesma, K.R., Chang, K.T., et al. In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother 56 (2012), 3753–3757.
31. 31 Livermore, D.M., Warner, M., Mushtaq, S., Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother 68:10 (2013), 2286–2290.
32. 32 Young K, Hackel M, Lascols C, et al. Response to imipenem plus MK-7655, a novel β-lactamase inhibitor, among 212 recent clinical isolates of P. aeruginosa, Abstr 1620, abstr IDSA Week 2012. San Diego (CA), October 17–21, 2012.
33. 33 Morinaka A, Tsutsumi Y, Yamada M, et al. F-946: OP0595, a novel serine-β-lactamase inhibitor: mode of action as β-lactamase inhibitor, antibiotic agent and β-lactam enhancer. Abstr 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, September 5–9, 2014.
34. 34 Ishii Y, Tsutsumi Y, Yoshizumi A, et al. F-953: OP0595, a novel serine-β-lactamase inhibitor: enzymatic studies of OP0595 against serine-β-lactamases. Abstr 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, September 5–9, 2014.
35. 35 Morinaka, A., Tsutsumi, Y., Yamada, M., et al. OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam ‘enhancer’. J Antimicrob Chemother 70:10 (2015), 2779–2786.
36. 36 Mendes RE, Rhomberg P, Becker H, et al. F-1188: Activity of β-lactam agents tested in combination with novel β-lactamase inhibitor compounds against Enterobacteriaceae producing extended-spectrum β-lactamases. Abstr 53rd International Interscience Conference on Antimicrobial Agents Chemotherapy. Denver (CO), September 10–13, 2013.
37. 37 Mendes RE, Rhomberg PR, Becker HK, et al. F-1189: β-lactam activity tested in combination with β-lactamase inhibitor candidates against Enterobacteriaceae producing class A, B and D carbapenemases. Abstr 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Denver (CO), September 10–13, 2013.
38. 38 Salama SM, Brouillette E, Malouin F, et al. F-1191: mechanistic studies of FPI-1465 a novel β-lactamase inhibitor. Abstr 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, September 5–9, 2014.
39. 39 Qin, W., Panunzio, M., Biondi, S., β-Lactam antibiotics renaissance. Antibiotics 3 (2014), 193–215.
40. 40 VanScoy, B.D., Trang, M., McCauley, J., et al. Pharmacokinetics-Pharmacodynamics of a Novel Beta-Lactamase Inhibitor, CB-618, in Combination with Meropenem in an. In Vitro Infection Model. Antimicrob Agents Chemother, 2016 [Epub ahead of print].
41. 41 Kiener, P.A., Waley, S.G., Reversible inhibitors of penicillinases. Biochem J 169 (1978), 197–204.
42. 42 Beesley, T., Gascoyne, N., Knott-Hunziker, V., et al. The inhibition of class C β-lactamases by boronic acids. Biochem J 209 (1983), 229–233.
43. 43 Hecker, S.J., Reddy, K.R., Totrov, M., et al. Discovery of a cyclic boronic acid β-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases. J Med Chem 58 (2015), 3682–3692.
44. 44 Livermore, D.M., Mushtaq, S., Activity of biapenem (RPX2003) combined with the boronate β-lactamase inhibitor RPX7009 against carbapenem-resistant enterobacteriaceae. J Antimicrob Chemother 68 (2013), 1825–1831.
45. 45 Lapuebla, A., Abdallah, M., Olafisoye, O., et al. Activity of meropenem combined with RPX7009, a novel β-lactamase inhibitor, against Gram-negative clinical isolates in New York City. Antimicrob Agents Chemother 59:8 (2015), 4856–4860.
46. 46 Goldstein, E.J., Citron, D.M., Tyrrell, K.L., et al. In vitro activity of biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria. Antimicrob Agents Chemother 57 (2013), 2620–2630.
47. 47 Powers, R.A., Blazquez, J., Weston, G.S., et al. The complexed structure and antimicrobial activity of a non-β-lactam inhibitor of AmpC β-lactamase. Protein Sci 8 (1999), 2330–2337.
48. 48 Rojas, L.J., Taracila, M.A., Papp-Wallace, K.M., et al. Boronic Acid Transition State Inhibitors Active against KPC and Other Class A β-Lactamases: Structure-Activity Relationships as a Guide to Inhibitor Design. Antimicrob Agents Chemother 60:3 (2016), 1751–1759.
49. 49 Eidam, O., Romagnoli, C., Caselli, E., et al. Design, synthesis, crystal structures, and antimicrobial activity of sulfonamide boronic acids as β-lactamase inhibitors. J Med Chem 53 (2010), 7852–7863.
50. 50 Crandon, J.L., Nicolau, D.P., In vivo activities of simulated human doses of cefepime and cefepime-AAI101 against multidrug-resistant Gram-negative Enterobacteriaceae. Antimicrob Agents Chemother 59 (2015), 2688–2694.
51. 51 Bou, G., Santillana, E., Sheri, A., et al. Design, synthesis, and crystal structures of 6-alkylidene-2'-substituted penicillanic acid sulfones as potent inhibitors of Acinetobacter baumannii OXA-24 carbapenemase. J Am Chem Soc 132 (2010), 13320–13331.
52. 52 Majumdar, S., Pratt, R.F., Inhibition of class A and C β-lactamases by diaroyl phosphates. Biochemistry 48 (2009), 8285–8292.
53. 53 Adediran, S.A., Nukaga, M., Baurin, S., et al. Inhibition of class D β-lactamases by acyl phosphates and phosphonates. Antimicrob Agents Chemother 49 (2005), 4410–4412.
54. 54 Lassaux, P., Hamel, M., Gulea, M., et al. Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-β-lactamases. J Med Chem 53 (2010), 4862–4876.
55. 55 Martell LA, Rahil G, Vaisburg A, et al. C1–1373: novel β-lactamase inhibitor potentiates and extends the antibacterial activity of imipenem against β-lactam-resistant P. aeruginosa and K. pneumoniae. Abstr 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco (CA), September 12–15, 2009.
56. 56 Poeylaut-Palena, A.A., Tomatis, P.E., Karsisiotis, A.I., et al. A minimalistic approach to identify substrate binding features in B1 metallo-β-lactamases. Bioorg Med Chem Lett 17 (2007), 5171–5174.
57. 57 Sakurai, Y., Yoshida, Y., Saitoh, K., et al. Characteristics of aztreonam as a substrate, inhibitor and inducer for β-lactamases. J Antibiot (Tokyo) 43 (1990), 403–410.
58. 58 Papp-Wallace, K.M., Mallo, S., Bethel, C.R., et al. A kinetic analysis of the inhibition of FOX-4 β-lactamase, a plasmid-mediated AmpC cephalosporinase, by monocyclic β-lactams and carbapenems. J Antimicrob Chemother 69 (2014), 682–690.
59. 59 Page, M.G., Dantier, C., Desarbre, E., In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant Gram-negative bacilli. Antimicrob Agents Chemother 54 (2010), 2291–2302.
60. 60 Mushtaq, S., Warner, M., Livermore, D., Activity of the siderophore monobactam BAL30072 against multiresistant non-fermenters. J Antimicrob Chemother 65 (2010), 266–270.
61. 61 Russo, T.A., Page, M.G., Beanan, J.M., et al. In vivo and in vitro activity of the siderophore monosulfactam BAL30072 against Acinetobacter baumannii. J Antimicrob Chemother 66 (2011), 867–873.
62. 62 Mima, T., Kvitko, B.H., Rholl, D.A., et al. In vitro activity of BAL30072 against Burkholderia pseudomallei. Int J Antimicrob Agents 38 (2011), 157–159.
63. 63 Hofer, B., Dantier, C., Gebhardt, K., et al. Combined effects of the siderophore monosulfactam BAL30072 and carbapenems on multidrug-resistant Gram-negative bacilli. J Antimicrob Chemother 68 (2013), 1120–1129.
64. 64 Livermore, D.M., Mushtaq, S., Warner, M., Activity of BAL30376 (monobactam BAL19764 + BAL29880 + clavulanate) versus Gram-negative bacteria with characterized resistance mechanisms. J Antimicrob Chemother 65 (2010), 2382–2395.
65. 65 Page, M.G., Dantier, C., Desarbre, E., et al. In vitro and in vivo properties of BAL30376, a β-lactam and dual β-lactamase inhibitor combination with enhanced activity against Gram-negative bacilli that express multiple β-lactamases. Antimicrob Agents Chemother 55 (2011), 1510–1519.
66. 66 Chen, H., Blizzard, T.A., Kim, S., et al. Side chain SAR of bicyclic β-lactamase inhibitors (BLIs). 2. N-Alkylated and open chain analogs of MK-8712. Bioorg Med Chem Lett 21 (2011), 4267–4270.
67. 67 Blizzard, T.A., Chen, H., Kim, S., et al. Side chain SAR of bicyclic β-lactamase inhibitors (BLIs). 1. Discovery of a class C BLI for combination with imipinem. Bioorg Med Chem Lett 20 (2010), 918–921.
68. 68 Mitton-Fry, M.J., Arcari, J.T., Brown, M.F., et al. Novel monobactams utilizing a siderophore uptake mechanism for the treatment of Gram-negative infections. Bioorg Med Chem Lett 22 (2012), 5989–5994.
69. 69 Brown, M.F., Mitton-Fry, M.J., Arcari, J.T., et al. Pyridone-conjugated monobactam antibiotics with Gram-negative activity. J Med Chem 56 (2013), 5541–5552.
70. 70 Nishida, K., Kunugita, C., Uji, T., et al. In vitro and in vivo activities of Syn2190, a novel β-lactamase inhibitor. Antimicrob Agents Chemother 43 (1999), 1895–1900.
71. 71 Ito, A., Kohira, N., Bouchillon, S.K., et al. In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. J Antimicrob Chemother 71:3 (2016), 670–677.
72. 72 Ishii Y, Horiyama T, Nakamura R, et al. F-1557: S-649266, a novel siderophore cephalosporin: III. Stability against clinically relevant β-lactamases. Abstr 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, September 5–9, 2014.
73. 73 Ito A, Yoshizawa H, Nakamura R, et al. F-1562: S-649266, a novel siderophore cephalosporin: I. In vitro activity against Gram-negative bacteria including multidrug-resistant strains. Abstr 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, September 5–9, 2014.
74. 74 Horiyama T, Singley CM, Nakamura R, et al. F-1556: S-649266, a novel siderophore cephalosporin: VIII. Efficacy against Pseudomonas aeruginosa and Acinetobacter baumannii in rat lung infection model with humanized exposure profile of 2 gram dose with 1 hour and 3 hours infusion. Abstr 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, September 5–9, 2014.
75. 75 Nakamura R, Toba S, Tsuji M, et al. F-1558: S-649266, a novel siderophore cephalosporin: IV. In vivo efficacy in various murine infection models. Abstr 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, September 5–9, 2014.
76. 76 Joo HY, Kim DI, Kowalik E, et al. F1-1202: FSI–1671, a novel anti-Acinetobacter carbapenem: in vivo efficacy against carbapenem-resistance Gram-negative bacterial infection. Abstr 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Denver (CO), September 10–13, 2013.
77. 77 Joo HY, Kim DI, Kowalik E, et al. F1–143: efficacy of FSI-1686 in animal model of carbapenem-resistance Gram-negative bacterial infection. Abstr 51st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago (IL), September 17–20, 2011.
78. 78 Mojica, M.F., Mahler, S.G., Bethel, C.R., et al. Exploring the role of residue 228 in substrate and inhibitor recognition by VIM metallo-β-lactamases. Biochemistry 54 (2015), 3183–3196.
79. 79 Ishii, Y., Eto, M., Mano, Y., et al. In vitro potentiation of carbapenems with ME1071, a novel metallo-β-lactamase inhibitor, against metallo-β-lactamase- producing Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 54 (2010), 3625–3629.
80. 80 Livermore, D.M., Mushtaq, S., Morinaka, A., et al. Activity of carbapenems with ME1071 (disodium 2,3-diethylmaleate) against Enterobacteriaceae and Acinetobacter spp. with carbapenemases, including NDM enzymes. J Antimicrob Chemother 68 (2013), 153–158.
81. 81 Yamada, K., Yanagihara, K., Kaku, N., et al. In vivo efficacy of biapenem with ME1071, a novel metallo-β-lactamase (MBL) inhibitor, in a murine model mimicking ventilator-associated pneumonia caused by MBL-producing Pseudomonas aeruginosa. Int J Antimicrob Agents 42 (2013), 238–243.